Rockefeller Capital Management L.P.
Position in ANIK — Anika Therapeutics, Inc.
CIK 1739439
NEW YORK, NY
Position in ANIK
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$15,544
+$13,488 QoQ
Shares Held
1,072
+400.9% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 20%
Shared 0%
None 80%
Common Shares in ANIK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Rockefeller Capital Management L.P. holds $133,569,034 across 49 Drug Manufacturers - Specialty & Generic names. ANIK ranks #27 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
|
5,103,509 | $51,086,123 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
282,097 | $37,163,457 | |
| 3 | ZTS |
Zoetis Inc.
|
253,206 | $29,931,479 | |
| 4 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
173,438 | $8,351,039 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
64,920 | $1,553,534 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
1,562 | $926,232 | |
| 7 | VTRS |
Viatris Inc
|
59,826 | $808,247 | |
| 8 | RDY |
Dr Reddys Laboratories Ltd
|
47,612 | $659,425 |
All Filings in ANIK
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $15,544 | 1,072 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $2,056 | 214 | Shares | Defined | 2026-03-17 | |
| 2022-12-31 | $384 | 13 | Shares | Defined | 2023-03-06 | |
| 2022-09-30 | $309 | 13 | Shares | Defined | 2022-11-02 | |
| 2022-06-30 | $691 | 31 | Shares | Defined | 2022-08-12 | |
| 2020-03-31 | $28,910 | 1,000 | Shares | Defined | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||